OBJECTIVE: To estimate the incidence of influenza-virus-associated severe pneumonia among Salvadorian children aged < 5 years. METHODS: Data on children aged < 5 years admitted with severe pneumonia to a sentinel hospital in the western region were collected weekly. Nasal and oropharyngeal swab specimens were collected from a convenience sample of case patients for respiratory virus testing. A health-care utilization survey was conducted in the hospital catchment area to determine the proportion of residents who sought care at the hospital. The incidence of influenza-virus-associated severe pneumonia among all Salvadorian children aged < 5 years was estimated from surveillance and census data, with adjustment for health-care utilization. Influenza virus strains were characterized by the United States Centers for Disease Control and Prevention to determine their correspondence with northern and southern hemisphere influenza vaccine formulations. FINDINGS: Physicians identified 2554 cases of severe pneumonia. Samples from 608 cases were tested for respiratory viruses and 37 (6%) were positive for influenza virus. The estimated incidence of influenza-virus-associated severe pneumonia was 3.2 cases per 1000 person-years (95% confidence interval, CI: 2.8-3.7) overall, 1.5 cases per 1000 person-years (95% CI: 1.0-2.0) during 2008, 7.6 cases per 1000 person-years (95% CI: 6.5-8.9) during 2009 and 0.6 cases per 1000 person-years (95% CI: 0.3-1.0) during 2010. Northern and southern hemisphere vaccine formulations matched influenza virus strains isolated during 2008 and 2010. CONCLUSION: Influenza-virus-associated severe pneumonia occurred frequently among young Salvadorian children during 2008-2010. Antigens in northern and southern hemisphere influenza vaccine formulations corresponded to circulating strains.
OBJECTIVE: To estimate the incidence of influenza-virus-associated severe pneumonia among Salvadorian children aged < 5 years. METHODS: Data on children aged < 5 years admitted with severe pneumonia to a sentinel hospital in the western region were collected weekly. Nasal and oropharyngeal swab specimens were collected from a convenience sample of case patients for respiratory virus testing. A health-care utilization survey was conducted in the hospital catchment area to determine the proportion of residents who sought care at the hospital. The incidence of influenza-virus-associated severe pneumonia among all Salvadorian children aged < 5 years was estimated from surveillance and census data, with adjustment for health-care utilization. Influenza virus strains were characterized by the United States Centers for Disease Control and Prevention to determine their correspondence with northern and southern hemisphere influenza vaccine formulations. FINDINGS: Physicians identified 2554 cases of severe pneumonia. Samples from 608 cases were tested for respiratory viruses and 37 (6%) were positive for influenza virus. The estimated incidence of influenza-virus-associated severe pneumonia was 3.2 cases per 1000 person-years (95% confidence interval, CI: 2.8-3.7) overall, 1.5 cases per 1000 person-years (95% CI: 1.0-2.0) during 2008, 7.6 cases per 1000 person-years (95% CI: 6.5-8.9) during 2009 and 0.6 cases per 1000 person-years (95% CI: 0.3-1.0) during 2010. Northern and southern hemisphere vaccine formulations matched influenza virus strains isolated during 2008 and 2010. CONCLUSION:Influenza-virus-associated severe pneumonia occurred frequently among young Salvadorian children during 2008-2010. Antigens in northern and southern hemisphere influenza vaccine formulations corresponded to circulating strains.
Authors: Eduardo Azziz-Baumgartner; A S M Alamgir; Mustafizur Rahman; Nusrat Homaira; Badrul Munir Sohel; M A Yushuf Sharker; Rashid Uz Zaman; Jacob Dee; Emily S Gurley; Abdullah Al Mamun; Syeda Mah-E-Muneer; Alicia M Fry; Marc-Alain Widdowson; Joseph Bresee; Stephen Lindstrom; Tasnim Azim; Abdullah Brooks; Goutam Podder; M Jahangir Hossain; Mahmudur Rahman; Stephen P Luby Journal: Bull World Health Organ Date: 2011-10-04 Impact factor: 9.408
Authors: Noelle-Angelique M Molinari; Ismael R Ortega-Sanchez; Mark L Messonnier; William W Thompson; Pascale M Wortley; Eric Weintraub; Carolyn B Bridges Journal: Vaccine Date: 2007-04-20 Impact factor: 3.641
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda Journal: JAMA Date: 2004-09-15 Impact factor: 56.272
Authors: Brian S Finkelman; Cécile Viboud; Katia Koelle; Matthew J Ferrari; Nita Bharti; Bryan T Grenfell Journal: PLoS One Date: 2007-12-12 Impact factor: 3.240
Authors: Nathalie El Omeiri; Eduardo Azziz-Baumgartner; Wilfrido Clará; Guiselle Guzmán-Saborío; Miguel Elas; Homer Mejía; Ida Berenice Molina; Yadira De Molto; Sara Mirza; Marc-Alain Widdowson; Alba María Ropero-Álvarez Journal: BMC Public Health Date: 2015-07-17 Impact factor: 3.295
Authors: Yeny O Tinoco; Eduardo Azziz-Baumgartner; Timothy M Uyeki; Hugo R Rázuri; Matthew R Kasper; Candice Romero; Maria E Silva; Mark P Simons; Giselle M Soto; Marc-Alain Widdowson; Robert H Gilman; Daniel G Bausch; Joel M Montgomery Journal: Clin Infect Dis Date: 2017-10-16 Impact factor: 9.079
Authors: Sharifa Nasreen; Stephen P Luby; W Abdullah Brooks; Nusrat Homaira; Abdullah Al Mamun; Mejbah Uddin Bhuiyan; Mustafizur Rahman; Dilruba Ahmed; Jaynal Abedin; Mahmudur Rahman; A S M Alamgir; Alicia M Fry; Peter Kim Streatfield; Anisur Rahman; Joseph Bresee; Marc-Alain Widdowson; Eduardo Azziz-Baumgartner Journal: PLoS One Date: 2014-02-25 Impact factor: 3.240
Authors: Eduardo Jorge da Fonseca Lima; Débora Ellen Pessoa Lima; George Henrique Cordeiro Serra; Maria Anaide Zacche S Abreu E Lima; Maria Júlia Gonçalves de Mello Journal: Ther Clin Risk Manag Date: 2016-06-14 Impact factor: 2.423